UOC
XENT

UBS O'Connor’s Intersect ENT, Inc XENT Stock Holding History

UBS O'Connor’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-70,000
Closed -$905K – 520
2016
Q2 		$905K Sell
70,000
-27,750
-28% -$434K 0.02% 317
2016
Q1 		$1.86M Buy
97,750
+550
+0.6% +$9.96K 0.02% 329
2015
Q4 		$2.19M Sell
97,200
-62,800
-39% -$1.24M 0.02% 309
2015
Q3 		$3.74M Buy
160,000
+90,000
+129% +$2.48M 0.04% 313
2015
Q2 		$2M Buy
70,000
+35,294
+102% +$925K 0.02% 418
2015
Q1 		$896K Sell
34,706
-26,053
-43% -$596K 0.01% 542
2014
Q4 		$1.13M Buy
+60,759
New +$1.09M 0.02% 346

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS O'Connor's XENT Position: Q3 2016 in Review

UBS O'Connor sold out of Intersect ENT, Inc (XENT) in Q3 2016, closing a stake of 70,000 shares — an estimated $905K sold.

UBS O'Connor first reported a position in XENT in Q4 2014 and held it in 7 quarters. The position peaked at $3.74M in Q3 2015. 98 funds tracked by Wall St. Rank hold XENT as of Q3 2016.

  • UBS O'Connor reported no remaining Intersect ENT, Inc position as of Q3 2016 after selling out during the quarter.
  • UBS O'Connor sold 70,000 Intersect ENT, Inc shares in Q3 2016, an estimated $905K.
  • UBS O'Connor first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 7 quarters.
  • UBS O'Connor's Intersect ENT, Inc position peaked at $3.74M in Q3 2015.
  • 98 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2016.

Based on UBS O'Connor's 13F filing for Q3 2016, filed 14 Nov 2016.